Biosimilars
SKU
MRR-4358917D6590
Region
Global
Publication Date
March 2024
Delivery
Immediate
2023
USD 40.70 billion
2030
USD 176.48 billion
2024
USD 49.91 billion
CAGR
23.31%

Biosimilars Market by Product (Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, Recombinant Peptides), Indication (Autoimmune Diseases, Blood Disorders, Chronic Diseases), Manufacturing - Global Forecast 2024-2030

[187 Pages Report] The Biosimilars Market size was estimated at USD 40.70 billion in 2023 and expected to reach USD 49.91 billion in 2024, at a CAGR 23.31% to reach USD 176.48 billion by 2030.

Biosimilars Market
To learn more about this report, request a free PDF copy
Biosimilars Market - Global Forecast 2024-2030
To learn more about this report, request a free PDF copy
FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Biosimilars Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Biosimilars Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Biosimilars Market, highlighting leading vendors and their innovative profiles. These include Alvotech, Amgen Inc., Apotex Inc., Biocon Limited, BioFactura, Inc., Biogen Inc., Boehringer Ingelheim International GmbH., Catalent, Inc, Celltrion Healthcare Co.,Ltd., Coherus BioSciences, Dr. Reddy's Laboratories Limited, Eden Biologics, Inc., F. Hoffmann-La Roche AG, Fresenius Kabi, Innovent Biologics, Inc., Intas Pharmaceuticals Ltd., Kashiv BioSciences, LLC., Merck & Co., Inc., NeuClone, Nippon Kayaku Co., Ltd., Novartis AG, Panacea Biotec Limited, Pfizer Inc., Samsung Bioepis Co., Ltd., Sanofi S.A., Shanghai Henlius Biotech, Inc., Teva Pharmaceutical Industries Ltd., and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Biosimilars Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Recombinant Glycosylated Proteins
      • Erythropoietin
      • Follitropin
      • Monoclonal Antibodies
        • Adalimumab
        • Infliximab
        • Rituximab
    • Recombinant Non-Glycosylated Proteins
      • Granulocyte Colony-Stimulating Factor
      • Insulin
      • Interferons
        • Interferon-Alpha
        • Interferon-Beta
      • Recombinant Human Growth Hormone
    • Recombinant Peptides
      • Calcitonin
      • Glucagon
  • Indication
    • Autoimmune Diseases
    • Blood Disorders
    • Chronic Diseases
    • Growth Hormone Deficiency
    • Infectious Diseases
    • Oncology
  • Manufacturing
    • Contract Manufacturing
    • In-House Manufacturing

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Biosimilars Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Biosimilars Market?
  3. What are the technology trends and regulatory frameworks in the Biosimilars Market?
  4. What is the market share of the leading vendors in the Biosimilars Market?
  5. Which modes and strategic moves are suitable for entering the Biosimilars Market?

Table of Contents
  1. Preface
    1. Objectives of the Study
    2. Market Segmentation & Coverage
    3. Years Considered for the Study
    4. Currency & Pricing
    5. Language
    6. Stakeholders
  2. Research Methodology
    1. Define: Research Objective
    2. Determine: Research Design
    3. Prepare: Research Instrument
    4. Collect: Data Source
    5. Analyze: Data Interpretation
    6. Formulate: Data Verification
    7. Publish: Research Report
    8. Repeat: Report Update
  3. Executive Summary
  4. Market Overview
  5. Market Insights
    1. Market Dynamics
      1. Drivers
        1. Rising healthcare expenditure into the pharmaceutical industry
        2. Increasing demand for lower cost biosimilars drugs than original biologics
      2. Restraints
        1. Reluctance of physicians to prescribe biosimilars
      3. Opportunities
        1. Improvements in biosimilar production processes
        2. Supportive government initiative to develop biosimilars
      4. Challenges
        1. Stringent regulatory requirements and laws
    2. Market Segmentation Analysis
    3. Market Trend Analysis
    4. Cumulative Impact of High Inflation
    5. Porter’s Five Forces Analysis
      1. Threat of New Entrants
      2. Threat of Substitutes
      3. Bargaining Power of Customers
      4. Bargaining Power of Suppliers
      5. Industry Rivalry
    6. Value Chain & Critical Path Analysis
    7. Regulatory Framework
  6. Biosimilars Market, by Product
    1. Introduction
    2. Recombinant Glycosylated Proteins
    3. Recombinant Non-Glycosylated Proteins
    4. Recombinant Peptides
  7. Biosimilars Market, by Indication
    1. Introduction
    2. Autoimmune Diseases
    3. Blood Disorders
    4. Chronic Diseases
    5. Growth Hormone Deficiency
    6. Infectious Diseases
    7. Oncology
  8. Biosimilars Market, by Manufacturing
    1. Introduction
    2. Contract Manufacturing
    3. In-House Manufacturing
  9. Americas Biosimilars Market
    1. Introduction
    2. Argentina
    3. Brazil
    4. Canada
    5. Mexico
    6. United States
  10. Asia-Pacific Biosimilars Market
    1. Introduction
    2. Australia
    3. China
    4. India
    5. Indonesia
    6. Japan
    7. Malaysia
    8. Philippines
    9. Singapore
    10. South Korea
    11. Taiwan
    12. Thailand
    13. Vietnam
  11. Europe, Middle East & Africa Biosimilars Market
    1. Introduction
    2. Denmark
    3. Egypt
    4. Finland
    5. France
    6. Germany
    7. Israel
    8. Italy
    9. Netherlands
    10. Nigeria
    11. Norway
    12. Poland
    13. Qatar
    14. Russia
    15. Saudi Arabia
    16. South Africa
    17. Spain
    18. Sweden
    19. Switzerland
    20. Turkey
    21. United Arab Emirates
    22. United Kingdom
  12. Competitive Landscape
    1. Market Share Analysis, 2023
    2. FPNV Positioning Matrix, 2023
    3. Competitive Scenario Analysis
  13. Competitive Portfolio
    1. Key Company Profiles
    2. Key Product Portfolio
  14. List of Figures [Total: 22]
    1. BIOSIMILARS MARKET RESEARCH PROCESS
    2. BIOSIMILARS MARKET SIZE, 2023 VS 2030
    3. GLOBAL BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
    4. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
    5. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
    6. BIOSIMILARS MARKET DYNAMICS
    7. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
    8. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
    9. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
    10. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
    11. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2023 VS 2030 (%)
    12. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2023 VS 2024 VS 2030 (USD MILLION)
    13. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    14. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    15. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
    16. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
    17. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    18. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    19. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    20. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    21. BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2023
    22. BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, 2023
  15. List of Tables [Total: 738]
    1. BIOSIMILARS MARKET SEGMENTATION & COVERAGE
    2. UNITED STATES DOLLAR EXCHANGE RATE, 2018–2023
    3. GLOBAL BIOSIMILARS MARKET SIZE, 2018-2023 (USD MILLION)
    4. GLOBAL BIOSIMILARS MARKET SIZE, 2024-2030 (USD MILLION)
    5. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
    6. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
    7. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    8. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    9. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, BY REGION, 2018-2023 (USD MILLION)
    10. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, BY REGION, 2024-2030 (USD MILLION)
    11. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    12. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    13. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2018-2023 (USD MILLION)
    14. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2024-2030 (USD MILLION)
    15. GLOBAL BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, BY REGION, 2018-2023 (USD MILLION)
    16. GLOBAL BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, BY REGION, 2024-2030 (USD MILLION)
    17. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
    18. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
    19. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    20. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    21. GLOBAL BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2023 (USD MILLION)
    22. GLOBAL BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2024-2030 (USD MILLION)
    23. GLOBAL BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2023 (USD MILLION)
    24. GLOBAL BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2024-2030 (USD MILLION)
    25. GLOBAL BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2023 (USD MILLION)
    26. GLOBAL BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY REGION, 2024-2030 (USD MILLION)
    27. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY REGION, 2018-2023 (USD MILLION)
    28. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY REGION, 2024-2030 (USD MILLION)
    29. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    30. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    31. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2018-2023 (USD MILLION)
    32. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2024-2030 (USD MILLION)
    33. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN, BY REGION, 2018-2023 (USD MILLION)
    34. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN, BY REGION, 2024-2030 (USD MILLION)
    35. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2023 (USD MILLION)
    36. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, BY REGION, 2024-2030 (USD MILLION)
    37. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    38. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    39. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, BY REGION, 2018-2023 (USD MILLION)
    40. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, BY REGION, 2024-2030 (USD MILLION)
    41. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, BY REGION, 2018-2023 (USD MILLION)
    42. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, BY REGION, 2024-2030 (USD MILLION)
    43. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2018-2023 (USD MILLION)
    44. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2024-2030 (USD MILLION)
    45. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY REGION, 2018-2023 (USD MILLION)
    46. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY REGION, 2024-2030 (USD MILLION)
    47. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    48. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    49. GLOBAL BIOSIMILARS MARKET SIZE, BY CALCITONIN, BY REGION, 2018-2023 (USD MILLION)
    50. GLOBAL BIOSIMILARS MARKET SIZE, BY CALCITONIN, BY REGION, 2024-2030 (USD MILLION)
    51. GLOBAL BIOSIMILARS MARKET SIZE, BY GLUCAGON, BY REGION, 2018-2023 (USD MILLION)
    52. GLOBAL BIOSIMILARS MARKET SIZE, BY GLUCAGON, BY REGION, 2024-2030 (USD MILLION)
    53. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    54. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    55. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2023 (USD MILLION)
    56. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2024-2030 (USD MILLION)
    57. GLOBAL BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2018-2023 (USD MILLION)
    58. GLOBAL BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2024-2030 (USD MILLION)
    59. GLOBAL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, BY REGION, 2018-2023 (USD MILLION)
    60. GLOBAL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, BY REGION, 2024-2030 (USD MILLION)
    61. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY REGION, 2018-2023 (USD MILLION)
    62. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY REGION, 2024-2030 (USD MILLION)
    63. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
    64. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
    65. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
    66. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
    67. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    68. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    69. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, BY REGION, 2018-2023 (USD MILLION)
    70. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, BY REGION, 2024-2030 (USD MILLION)
    71. GLOBAL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2018-2023 (USD MILLION)
    72. GLOBAL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2024-2030 (USD MILLION)
    73. AMERICAS BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    74. AMERICAS BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    75. AMERICAS BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    76. AMERICAS BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    77. AMERICAS BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    78. AMERICAS BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    79. AMERICAS BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    80. AMERICAS BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    81. AMERICAS BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    82. AMERICAS BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    83. AMERICAS BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    84. AMERICAS BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    85. AMERICAS BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    86. AMERICAS BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    87. AMERICAS BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    88. AMERICAS BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    89. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
    90. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
    91. ARGENTINA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    92. ARGENTINA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    93. ARGENTINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    94. ARGENTINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    95. ARGENTINA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    96. ARGENTINA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    97. ARGENTINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    98. ARGENTINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    99. ARGENTINA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    100. ARGENTINA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    101. ARGENTINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    102. ARGENTINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    103. ARGENTINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    104. ARGENTINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    105. ARGENTINA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    106. ARGENTINA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    107. BRAZIL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    108. BRAZIL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    109. BRAZIL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    110. BRAZIL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    111. BRAZIL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    112. BRAZIL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    113. BRAZIL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    114. BRAZIL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    115. BRAZIL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    116. BRAZIL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    117. BRAZIL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    118. BRAZIL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    119. BRAZIL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    120. BRAZIL BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    121. BRAZIL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    122. BRAZIL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    123. CANADA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    124. CANADA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    125. CANADA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    126. CANADA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    127. CANADA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    128. CANADA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    129. CANADA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    130. CANADA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    131. CANADA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    132. CANADA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    133. CANADA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    134. CANADA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    135. CANADA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    136. CANADA BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    137. CANADA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    138. CANADA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    139. MEXICO BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    140. MEXICO BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    141. MEXICO BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    142. MEXICO BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    143. MEXICO BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    144. MEXICO BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    145. MEXICO BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    146. MEXICO BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    147. MEXICO BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    148. MEXICO BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    149. MEXICO BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    150. MEXICO BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    151. MEXICO BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    152. MEXICO BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    153. MEXICO BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    154. MEXICO BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    155. UNITED STATES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    156. UNITED STATES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    157. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    158. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    159. UNITED STATES BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    160. UNITED STATES BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    161. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    162. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    163. UNITED STATES BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    164. UNITED STATES BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    165. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    166. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    167. UNITED STATES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    168. UNITED STATES BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    169. UNITED STATES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    170. UNITED STATES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    171. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
    172. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
    173. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    174. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    175. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    176. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    177. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    178. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    179. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    180. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    181. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    182. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    183. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    184. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    185. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    186. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    187. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    188. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    189. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
    190. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
    191. AUSTRALIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    192. AUSTRALIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    193. AUSTRALIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    194. AUSTRALIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    195. AUSTRALIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    196. AUSTRALIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    197. AUSTRALIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    198. AUSTRALIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    199. AUSTRALIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    200. AUSTRALIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    201. AUSTRALIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    202. AUSTRALIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    203. AUSTRALIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    204. AUSTRALIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    205. AUSTRALIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    206. AUSTRALIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    207. CHINA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    208. CHINA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    209. CHINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    210. CHINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    211. CHINA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    212. CHINA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    213. CHINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    214. CHINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    215. CHINA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    216. CHINA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    217. CHINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    218. CHINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    219. CHINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    220. CHINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    221. CHINA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    222. CHINA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    223. INDIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    224. INDIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    225. INDIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    226. INDIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    227. INDIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    228. INDIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    229. INDIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    230. INDIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    231. INDIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    232. INDIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    233. INDIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    234. INDIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    235. INDIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    236. INDIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    237. INDIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    238. INDIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    239. INDONESIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    240. INDONESIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    241. INDONESIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    242. INDONESIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    243. INDONESIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    244. INDONESIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    245. INDONESIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    246. INDONESIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    247. INDONESIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    248. INDONESIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    249. INDONESIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    250. INDONESIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    251. INDONESIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    252. INDONESIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    253. INDONESIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    254. INDONESIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    255. JAPAN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    256. JAPAN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    257. JAPAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    258. JAPAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    259. JAPAN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    260. JAPAN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    261. JAPAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    262. JAPAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    263. JAPAN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    264. JAPAN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    265. JAPAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    266. JAPAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    267. JAPAN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    268. JAPAN BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    269. JAPAN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    270. JAPAN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    271. MALAYSIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    272. MALAYSIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    273. MALAYSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    274. MALAYSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    275. MALAYSIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    276. MALAYSIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    277. MALAYSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    278. MALAYSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    279. MALAYSIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    280. MALAYSIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    281. MALAYSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    282. MALAYSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    283. MALAYSIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    284. MALAYSIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    285. MALAYSIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    286. MALAYSIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    287. PHILIPPINES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    288. PHILIPPINES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    289. PHILIPPINES BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    290. PHILIPPINES BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    291. PHILIPPINES BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    292. PHILIPPINES BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    293. PHILIPPINES BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    294. PHILIPPINES BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    295. PHILIPPINES BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    296. PHILIPPINES BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    297. PHILIPPINES BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    298. PHILIPPINES BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    299. PHILIPPINES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    300. PHILIPPINES BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    301. PHILIPPINES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    302. PHILIPPINES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    303. SINGAPORE BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    304. SINGAPORE BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    305. SINGAPORE BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    306. SINGAPORE BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    307. SINGAPORE BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    308. SINGAPORE BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    309. SINGAPORE BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    310. SINGAPORE BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    311. SINGAPORE BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    312. SINGAPORE BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    313. SINGAPORE BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    314. SINGAPORE BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    315. SINGAPORE BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    316. SINGAPORE BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    317. SINGAPORE BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    318. SINGAPORE BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    319. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    320. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    321. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    322. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    323. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    324. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    325. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    326. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    327. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    328. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    329. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    330. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    331. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    332. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    333. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    334. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    335. TAIWAN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    336. TAIWAN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    337. TAIWAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    338. TAIWAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    339. TAIWAN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    340. TAIWAN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    341. TAIWAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    342. TAIWAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    343. TAIWAN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    344. TAIWAN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    345. TAIWAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    346. TAIWAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    347. TAIWAN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    348. TAIWAN BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    349. TAIWAN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    350. TAIWAN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    351. THAILAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    352. THAILAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    353. THAILAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    354. THAILAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    355. THAILAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    356. THAILAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    357. THAILAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    358. THAILAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    359. THAILAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    360. THAILAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    361. THAILAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    362. THAILAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    363. THAILAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    364. THAILAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    365. THAILAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    366. THAILAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    367. VIETNAM BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    368. VIETNAM BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    369. VIETNAM BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    370. VIETNAM BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    371. VIETNAM BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    372. VIETNAM BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    373. VIETNAM BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    374. VIETNAM BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    375. VIETNAM BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    376. VIETNAM BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    377. VIETNAM BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    378. VIETNAM BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    379. VIETNAM BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    380. VIETNAM BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    381. VIETNAM BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    382. VIETNAM BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    383. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    384. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    385. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    386. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    387. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    388. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    389. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    390. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    391. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    392. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    393. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    394. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    395. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    396. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    397. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    398. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    399. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
    400. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
    401. DENMARK BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    402. DENMARK BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    403. DENMARK BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    404. DENMARK BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    405. DENMARK BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    406. DENMARK BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    407. DENMARK BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    408. DENMARK BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    409. DENMARK BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    410. DENMARK BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    411. DENMARK BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    412. DENMARK BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    413. DENMARK BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    414. DENMARK BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    415. DENMARK BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    416. DENMARK BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    417. EGYPT BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    418. EGYPT BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    419. EGYPT BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    420. EGYPT BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    421. EGYPT BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    422. EGYPT BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    423. EGYPT BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    424. EGYPT BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    425. EGYPT BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    426. EGYPT BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    427. EGYPT BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    428. EGYPT BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    429. EGYPT BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    430. EGYPT BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    431. EGYPT BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    432. EGYPT BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    433. FINLAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    434. FINLAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    435. FINLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    436. FINLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    437. FINLAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    438. FINLAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    439. FINLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    440. FINLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    441. FINLAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    442. FINLAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    443. FINLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    444. FINLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    445. FINLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    446. FINLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    447. FINLAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    448. FINLAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    449. FRANCE BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    450. FRANCE BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    451. FRANCE BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    452. FRANCE BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    453. FRANCE BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    454. FRANCE BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    455. FRANCE BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    456. FRANCE BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    457. FRANCE BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    458. FRANCE BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    459. FRANCE BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    460. FRANCE BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    461. FRANCE BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    462. FRANCE BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    463. FRANCE BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    464. FRANCE BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    465. GERMANY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    466. GERMANY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    467. GERMANY BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    468. GERMANY BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    469. GERMANY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    470. GERMANY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    471. GERMANY BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    472. GERMANY BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    473. GERMANY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    474. GERMANY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    475. GERMANY BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    476. GERMANY BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    477. GERMANY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    478. GERMANY BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    479. GERMANY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    480. GERMANY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    481. ISRAEL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    482. ISRAEL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    483. ISRAEL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    484. ISRAEL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    485. ISRAEL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    486. ISRAEL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    487. ISRAEL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    488. ISRAEL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    489. ISRAEL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    490. ISRAEL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    491. ISRAEL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    492. ISRAEL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    493. ISRAEL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    494. ISRAEL BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    495. ISRAEL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    496. ISRAEL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    497. ITALY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    498. ITALY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    499. ITALY BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    500. ITALY BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    501. ITALY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    502. ITALY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    503. ITALY BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    504. ITALY BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    505. ITALY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    506. ITALY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    507. ITALY BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    508. ITALY BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    509. ITALY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    510. ITALY BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    511. ITALY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    512. ITALY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    513. NETHERLANDS BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    514. NETHERLANDS BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    515. NETHERLANDS BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    516. NETHERLANDS BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    517. NETHERLANDS BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    518. NETHERLANDS BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    519. NETHERLANDS BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    520. NETHERLANDS BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    521. NETHERLANDS BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    522. NETHERLANDS BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    523. NETHERLANDS BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    524. NETHERLANDS BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    525. NETHERLANDS BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    526. NETHERLANDS BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    527. NETHERLANDS BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    528. NETHERLANDS BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    529. NIGERIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    530. NIGERIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    531. NIGERIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    532. NIGERIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    533. NIGERIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    534. NIGERIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    535. NIGERIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    536. NIGERIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    537. NIGERIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    538. NIGERIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    539. NIGERIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    540. NIGERIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    541. NIGERIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    542. NIGERIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    543. NIGERIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    544. NIGERIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    545. NORWAY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    546. NORWAY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    547. NORWAY BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    548. NORWAY BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    549. NORWAY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    550. NORWAY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    551. NORWAY BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    552. NORWAY BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    553. NORWAY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    554. NORWAY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    555. NORWAY BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    556. NORWAY BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    557. NORWAY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    558. NORWAY BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    559. NORWAY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    560. NORWAY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    561. POLAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    562. POLAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    563. POLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    564. POLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    565. POLAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    566. POLAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    567. POLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    568. POLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    569. POLAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    570. POLAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    571. POLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    572. POLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    573. POLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    574. POLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    575. POLAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    576. POLAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    577. QATAR BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    578. QATAR BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    579. QATAR BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    580. QATAR BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    581. QATAR BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    582. QATAR BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    583. QATAR BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    584. QATAR BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    585. QATAR BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    586. QATAR BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    587. QATAR BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    588. QATAR BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    589. QATAR BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    590. QATAR BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    591. QATAR BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    592. QATAR BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    593. RUSSIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    594. RUSSIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    595. RUSSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    596. RUSSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    597. RUSSIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    598. RUSSIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    599. RUSSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    600. RUSSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    601. RUSSIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    602. RUSSIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    603. RUSSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    604. RUSSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    605. RUSSIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    606. RUSSIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    607. RUSSIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    608. RUSSIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    609. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    610. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    611. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    612. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    613. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    614. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    615. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    616. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    617. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    618. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    619. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    620. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    621. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    622. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    623. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    624. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    625. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    626. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    627. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    628. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    629. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    630. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    631. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    632. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    633. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    634. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    635. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    636. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    637. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    638. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    639. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    640. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    641. SPAIN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    642. SPAIN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    643. SPAIN BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    644. SPAIN BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    645. SPAIN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    646. SPAIN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    647. SPAIN BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    648. SPAIN BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    649. SPAIN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    650. SPAIN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    651. SPAIN BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    652. SPAIN BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    653. SPAIN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    654. SPAIN BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    655. SPAIN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    656. SPAIN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    657. SWEDEN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    658. SWEDEN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    659. SWEDEN BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    660. SWEDEN BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    661. SWEDEN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    662. SWEDEN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    663. SWEDEN BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    664. SWEDEN BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    665. SWEDEN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    666. SWEDEN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    667. SWEDEN BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    668. SWEDEN BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    669. SWEDEN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    670. SWEDEN BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    671. SWEDEN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    672. SWEDEN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    673. SWITZERLAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    674. SWITZERLAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    675. SWITZERLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    676. SWITZERLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    677. SWITZERLAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    678. SWITZERLAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    679. SWITZERLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    680. SWITZERLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    681. SWITZERLAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    682. SWITZERLAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    683. SWITZERLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    684. SWITZERLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    685. SWITZERLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    686. SWITZERLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    687. SWITZERLAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    688. SWITZERLAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    689. TURKEY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    690. TURKEY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    691. TURKEY BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    692. TURKEY BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    693. TURKEY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    694. TURKEY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    695. TURKEY BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    696. TURKEY BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    697. TURKEY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    698. TURKEY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    699. TURKEY BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    700. TURKEY BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    701. TURKEY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    702. TURKEY BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    703. TURKEY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    704. TURKEY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    705. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    706. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    707. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    708. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    709. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    710. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    711. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    712. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    713. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    714. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    715. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    716. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    717. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    718. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    719. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    720. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    721. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
    722. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
    723. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    724. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    725. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2023 (USD MILLION)
    726. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2024-2030 (USD MILLION)
    727. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2023 (USD MILLION)
    728. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2024-2030 (USD MILLION)
    729. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2023 (USD MILLION)
    730. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2024-2030 (USD MILLION)
    731. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2023 (USD MILLION)
    732. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2024-2030 (USD MILLION)
    733. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
    734. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
    735. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2023 (USD MILLION)
    736. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2024-2030 (USD MILLION)
    737. BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2023
    738. BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, 2023
  16. List of Companies Mentioned [Total: 28]
    1. Alvotech
    2. Amgen Inc.
    3. Apotex Inc.
    4. Biocon Limited
    5. BioFactura, Inc.
    6. Biogen Inc.
    7. Boehringer Ingelheim International GmbH.
    8. Catalent, Inc
    9. Celltrion Healthcare Co.,Ltd.
    10. Coherus BioSciences
    11. Dr. Reddy's Laboratories Limited
    12. Eden Biologics, Inc.
    13. F. Hoffmann-La Roche AG
    14. Fresenius Kabi
    15. Innovent Biologics, Inc.
    16. Intas Pharmaceuticals Ltd.
    17. Kashiv BioSciences, LLC.
    18. Merck & Co., Inc.
    19. NeuClone
    20. Nippon Kayaku Co., Ltd.
    21. Novartis AG
    22. Panacea Biotec Limited
    23. Pfizer Inc.
    24. Samsung Bioepis Co., Ltd.
    25. Sanofi S.A.
    26. Shanghai Henlius Biotech, Inc.
    27. Teva Pharmaceutical Industries Ltd.
    28. Thermo Fisher Scientific, Inc.
Frequently Asked Questions
  1. How big is the Biosimilars Market?
    Ans. The Global Biosimilars Market size was estimated at USD 40.70 billion in 2023 and expected to reach USD 49.91 billion in 2024.
  2. What is the Biosimilars Market growth?
    Ans. The Global Biosimilars Market to grow USD 176.48 billion by 2030, at a CAGR of 23.31%
  3. When do I get the report?
    Ans. Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
  4. In what format does this report get delivered to me?
    Ans. We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
  5. How long has 360iResearch been around?
    Ans. We are approaching our 7th anniversary in 2024!
  6. What if I have a question about your reports?
    Ans. Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
  7. Can I share this report with my team?
    Ans. Absolutely yes, with the purchase of additional user licenses.
  8. Can I use your research in my presentation?
    Ans. Absolutely yes, so long as the 360iResearch cited correctly.
DOWNLOAD A FREE PDF
This free PDF includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.